Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Return on Sales (2016 - 2021)

Syndax Pharmaceuticals has reported Return on Sales over the past 7 years, most recently at 52.26% for Q3 2021.

  • Quarterly results put Return on Sales at 52.26% for Q3 2021, up 12.0% from a year ago — trailing twelve months through Sep 2021 was 52.26% (down 891.0% YoY), and the annual figure for FY2025 was 1.45%, up 1179.0%.
  • Return on Sales for Q3 2021 was 52.26% at Syndax Pharmaceuticals, roughly flat from 52.32% in the prior quarter.
  • Over the last five years, Return on Sales for SNDX hit a ceiling of 15.95% in Q4 2017 and a floor of 52.38% in Q3 2020.
  • Median Return on Sales over the past 5 years was 47.07% (2018), compared with a mean of 44.54%.
  • Biggest five-year swings in Return on Sales: soared 1970bps in 2017 and later crashed -3493bps in 2018.
  • Syndax Pharmaceuticals' Return on Sales stood at 15.95% in 2017, then tumbled by -219bps to 50.88% in 2018, then grew by 27bps to 37.38% in 2019, then crashed by -40bps to 52.26% in 2020, then changed by 0bps to 52.26% in 2021.
  • The last three reported values for Return on Sales were 52.26% (Q3 2021), 52.32% (Q2 2021), and 49.49% (Q1 2021) per Business Quant data.